Avalo Therapeutics Stock Today
| AVTX Stock | USD 7.99 0.22 2.83% |
PerformanceVery Weak
| Odds Of DistressLow
|
Avalo Therapeutics is trading at 7.99 as of the 20th of March 2025; that is 2.83 percent increase since the beginning of the trading day. The stock's open price was 7.77. Avalo Therapeutics has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Avalo Therapeutics, Inc. The company has 10.5 M outstanding shares of which 75.99 K shares are presently shorted by private and institutional investors with about 2.28 trading days to cover. More on Avalo Therapeutics
Moving against Avalo Stock
Avalo Stock Highlights
| President Board | Garry MD |
| Old Name | AVANTIUM |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, AMS Small Cap, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Avalo Therapeutics (AVTX) is traded on NASDAQ Exchange in USA. It is located in 540 Gaither Road, Rockville, MD, United States, 20850 and employs 19 people. Avalo Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.58 M. Avalo Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.5 M outstanding shares of which 75.99 K shares are presently shorted by private and institutional investors with about 2.28 trading days to cover.
Avalo Therapeutics currently holds about 11.25 M in cash with (30.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2.
Check Avalo Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Avalo Therapeutics is $81.58 Million. The majority of Avalo Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avalo Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avalo Therapeutics. Please pay attention to any change in the institutional holdings of Avalo Therapeutics as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Avalo Ownership Details
Avalo Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Avalo Therapeutics market risk premium is the additional return an investor will receive from holding Avalo Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0071 | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | 0.488 | |||
| Treynor Ratio | 0.026 |
Avalo Stock Against Markets
Avalo Therapeutics Corporate Management
| Blake MD | Scientific Advisor | Profile | |
| Barbara Slusher | Founder Board | Profile | |
| Maxim CFA | VP Relations | Profile | |
| Stephen Thomas | VP Discovery | Profile | |
| Christopher Sullivan | Chief Officer | Profile |
Already Invested in Avalo Therapeutics?
The danger of trading Avalo Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avalo Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avalo Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avalo Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.